Strength creep: why you end up stronger over time

Strength creep is a real experience, but it is barely a documented pattern — and the best evidence says the shelf moved more than you did. In the only study that has measured strength trajectory in pouch users, 16.8% went up, 13.2% went down and 51.4% never changed. Meanwhile the number on the tin was never the dose it looked like.

Ask around long enough and you will hear the same story: started on 3 mg, settled on 6 mg, and now the 6 mg feels like nothing. It is one of the most repeated claims in this category, and I went looking for the evidence behind it expecting to find a tidy pharmacological explanation. I did not find one. What I found instead was a premise that almost nobody has actually tested, and three better-evidenced reasons why the feeling is real even where the escalation is not.

That is a more useful article than the one I set out to write, so this is the one you get.

What the one study that measured it actually found

There is a single dataset anywhere that puts numbers on whether pouch users move up in strength over time. It sits in a 2026 paper in Frontiers in Public Health on 560 current pouch users who had a history of cigarette smoking, and the finding is not what the folklore predicts:

Strength trajectory categories were decreased (74/560, 13.2%), no change (288/560, 51.4%), increased (94/560, 16.8%), fluctuated (41/560, 7.3%), and switching as needed (54/560, 9.6%).

Going up is about four percentage points commoner than coming down, and half the sample never moved at all. That is not a creep; it is churn with a slight upward tilt.

I would not lean hard on those numbers either, and I want to be plain about why. It is cross-sectional, so every participant was asked to recall their own strength history rather than being followed forward. It was conducted in Saudi Arabia, where the market skews strong — “Among NP users, 10 mg was the most frequently chosen strength (405/560, 72.3%)”, which is above anything the FDA has authorised in the United States. And the trajectory figures appear in the body of the paper and a figure caption, not in the abstract, so anyone checking the abstract will not find them. The study was funded by a university endowment, not by industry: “This project was funded by KAU Endowment (WAQF) at King Abdulaziz University, Jeddah, Saudi Arabia.”

Beyond that one paper there is nothing. A 2026 scoping review of all population-based quantitative research on oral nicotine pouches located eleven studies in total and concluded that “Evidence regarding ONP use patterns among adolescents and adults appears to be lacking.” No prospective cohort has ever recorded what strength a pouch user buys and then watched it over time. The question has not been answered because it has not been asked.

What tolerance does and does not explain

The pharmacology of nicotine tolerance is genuinely well established — just not for the thing people use it to explain.

Chronic exposure changes the receptors. In Benowitz’s review in the Annual Review of Pharmacology and Toxicology: “Concurrent with this neuroadaptation is an increase in the number of nAChR binding sites in the brain. This increase is believed to represent upregulation in response to nicotine-mediated desensitization of receptors.” Note the direction of that sentence, because it is easy to state backwards. The extra receptors are a response to desensitisation. Nobody has shown that having more of them is what makes a person need a stronger pouch.

And tolerance is selective. The same review: “With repeated exposure to nicotine, tolerance (neuroadaptation) develops to some, but not all, of the effects of nicotine”. The question is which ones — and here the human experimental record is awkward for the creep story. When nicotine-naive volunteers were dosed for eight days in a 2001 study, “Tolerance developed to some, but not all, of these aversive effects.” The effects that faded were the unpleasant ones: nausea, the turning stomach, the dysphoria. Tolerance to the performance and cardiovascular effects was much weaker.

That is a mechanism for lifting a ceiling, not for hollowing out a reward. A beginner cannot physically tolerate 9 mg; six months later they can. Whether they need 9 mg is a different claim, and it is the one nobody has evidence for.

One thing that is solidly documented, and worth knowing because it explains the single most-noticed effect in the whole category: “Abstinence overnight allows considerable resensitization to the actions of nicotine.” The first pouch of the day hits harder because you spent eight hours not using nicotine. That is not creep. That is Tuesday.

The number on the tin was never the dose

Here is where the evidence is strong, and where I think the real explanation lives. The label on a pouch is a statement about how much nicotine is in it, not about how much reaches you. The gap between those two things is enormous, and it is driven by variables that appear nowhere on the can.

pH does more than milligrams. In a randomised crossover trial published in Clinical Pharmacology & Therapeutics, researchers took one single moist-snuff product, held the nicotine content constant, and chemically adjusted only its pH. The conclusion: “Nicotine PK substantially depends on its free-base proportion”, with more than a fourfold increase in peak plasma nicotine from pH 5.0 to pH 8.6. Same milligrams. Four times the delivered dose. I could not read that paper’s funding statement, so treat it with that caveat, but the mechanism is textbook — nicotine is a weak base, and as Benowitz puts it, “Nicotine is a weak base, with a pKa of 8.0.” Above that pH, more of it is in the free-base form that crosses a membrane easily.

Across 70 commercial tobacco-free nicotine products analysed for Tobacco Control, “The pH ranged from pH 4.68 to 9.49 and per cent freebase nicotine ranged from 0.0453% to 96.7%.” No manufacturer publishes a pH figure per product. The variable with the biggest effect on what you actually absorb is invisible to you at the point of purchase.

Most of the nicotine never leaves the pouch. A BAT-funded crossover study — “all authors were employees of BAT, which was the sponsor and funding source of this study” — measured extraction at fixed hold times: “Extracted nicotine was greater for the 11‐mg than for the 20‐mg NP, (10 min, 28.0% vs. 22.4%; 20 min, 35.8% vs. 29.6%; 30 min, 43.7% vs. 36.9%, respectively).” Read that twice. At a full half-hour hold, under half the labelled nicotine has come out — and the stronger pouch released a smaller fraction.

Independent, government-funded work agrees. A study funded by Germany’s Federal Institute for Risk Assessment — “The study was funded by intermural funding from the German Federal Institute for Risk Assessment”, reproducing the paper’s own typo — found that “participants only extracted 52% (14 ± 3.0 mg) of the nicotine contained in the 30 mg pouches and even less from the other pouches”, and summarised earlier work at hour-long holds: “Lunell et al. have reported mean extraction rates of 56%, 59%, and 50% for pouches with 3, 6, and 8 mg nicotine, respectively”.

And the ladder is not even monotonic. This is the sentence from that German study that I find hardest to argue with: “Relative bioavailability in relation to the 6 mg (analyzed 4.8 mg) pouch was 70% for the 20 mg (analyzed 16.3 mg) pouch and 165% for the 30 mg (analyzed 27.1 mg) pouch.” A 20 mg pouch delivered less nicotine than a 6 mg one. The authors’ own summary is the right way to hold this: “The nicotine release rate varies across products and needs to be known to estimate the nicotine delivery.”

The between-brand effect swamps the within-brand one. An Altria-funded study of its own products — “This study was funded by Altria Client Services LLC, and all authors are employees of Altria Client Services LLC.” — reported that “The mean nicotine C_max for NPs increased with nicotine level, ranging from 3.5 ng/mL (1.5 mg NP) to 15.4 ng/mL (8 mg NP)”. An independent study at Queen Mary, London, measured a 9 mg ZYN pouch at a peak of 27.9 ng/mL. Nearly identical labels, nearly double the delivered dose.

So a reader who “moved up” from 6 mg to 9 mg within one brand may have made a smaller change than a reader who switched brands and kept the number the same — and the second reader thinks they changed nothing at all. If you want this in more detail, I have written separately on why two 6 mg pouches from different brands feel completely different and on mg per pouch versus mg per gram.

It is worth adding that this entire literature leans one way. A review funded by the US National Institute on Drug Abuse and the FDA’s Center for Tobacco Products states it bluntly: “nearly all clinical studies on ONPs to date have been funded by the tobacco industry and are therefore subject to significant bias”. Two of the four strongest numbers above come from manufacturer-funded studies of the manufacturer’s own products. I have used them because they are the best measurements that exist, and I have named the funder every time.

The shelf got stronger, and that needs no theory at all

This is the explanation I had not expected and now think is the most important one, because it requires no assumption about anybody’s behaviour. In the United States, the strongest pouch you could legally buy nearly doubled in nineteen months, and the FDA’s own announcements date every step.

In January 2025 the authorised ceiling was 6 mg. In December 2025 it rose to 9 mg. In August 2026 it rose to 11 mg. The current authorised list “is up to date” and states that “There are 43 nicotine pouch products authorized by the FDA”, which “are the only nicotine pouch products that may be lawfully sold in the United States”, with page content current as of 21 August 2026. Those 43 products span exactly six strengths — 2, 3, 4, 6, 9 and 11 mg — from two companies, Helix Innovations and Swedish Match USA.

A person who started on pouches in early 2025 could not have bought anything above 6 mg legally. By late 2026 an 11 mg product is sitting on the same shelf. Some of what feels like a drift upward in the user is a drift upward in the market, and the FDA is careful to say that authorisation “does not mean these products are safe, nor are they “FDA approved.””

There is a sharper version of this argument in the literature, and it is worth printing even though it is a characterisation rather than a measurement. Writing in Clinical Pharmacology & Therapeutics, Benowitz argues that “Some tobacco companies have marketed low pH smokeless tobacco products as starter products” — the sentence continues to describe progressively higher-pH products that would promote and sustain dependence. If that is right, part of the ladder is a design decision, built on the one variable the label never shows. It is an assertion in a commentary without a citation attached, so I present it as his reading rather than as an established finding.

Flavour moves satisfaction without moving nicotine

The competing explanation that holds up best on the user’s side is not about nicotine at all.

In the German study above, every product tested reduced acute cigarette craving — including the one with no nicotine in it: “Use of all products has reduced acute cigarette craving, even the nicotine-free pouch.” That is a single acute session with fifteen non-habitual users, so I would not build a theory on it. But it points somewhere real: part of what a pouch does is oral, sensory and expectant, and none of that has a milligram figure.

A 2026 study by Swedish Match and Philip Morris employees compared flavoured against unflavoured pouches at matched strengths and found nicotine delivery equivalent while “participants rating the flavored varieties higher for satisfaction, product liking, and intent to use again”. Independent survey work points the same way: “The availability of preferred flavors was the most frequently reported” motivation for pouch use in a 2024 study in Nicotine & Tobacco Research.

So a person switching cans every few weeks in search of something that still tastes interesting will often end up holding a different strength as a side effect of chasing a flavour. That is brand churn with a strength figure attached, not escalation.

Hold time is the lever you already have

If the feeling you are chasing is “this does less than it used to”, the variable with the largest sourced effect is not the number on the tin. It is how long you keep the pouch in.

From the BAT data: “Nicotine delivery to the consumer increases with the duration of use.” On the same 11 mg product, extraction went from 28.0% at ten minutes to 43.7% at thirty — roughly a 56% increase in delivered nicotine with no change of product at all. Peak blood nicotine also arrives later as the hold lengthens, so a long hold is both a bigger dose and a slower one. Swallowing is not the escape route people imagine, either: “Only 1.8% of the nicotine measured in the reference NPs was detected in saliva collected over the 30 min use period.”

Going the other way, a 9 mg pouch is a lot of nicotine for someone not used to it. The Queen Mary researchers noted that “Three participants who were light smokers experienced nausea and one vomited”, and concluded that “ZYN pouches with 9 mg of nicotine may be too strong for light smokers”. If you are feeling the signs rather than the satisfaction, the signs of too much nicotine are worth reading before you buy anything stronger, and stepping down is a real option.

The four explanations, side by side

Explanation	What it claims	Evidence for it	My read
Pharmacological tolerance	The same dose stops working, so you need more	Receptor upregulation and selective tolerance are well established in smoking; the documented tolerance is substantially to the aversive effects	Real mechanism, wrong job. It lifts the ceiling rather than hollowing out the reward, and no pouch-specific data support escalation
The label never was the dose	You did not move up as much, or as little, as the number says	Fourfold pH effect on delivery; 22–44% extraction at 10–30 min; a 20 mg pouch delivering less than a 6 mg one; roughly double the peak from 9 mg ZYN versus 8 mg on!	The best-evidenced piece of the puzzle, and the one readers can act on
The shelf got stronger	Availability moved, not you	US authorised ceiling 6 mg (Jan 2025) → 9 mg (Dec 2025) → 11 mg (Aug 2026), each dated by the FDA	Needs no behavioural assumption at all. I think this is the most underrated explanation
Flavour and sensory drift	You were chasing taste and the strength followed	Flavour raised satisfaction and intent to use again at matched nicotine; a nicotine-free pouch reduced craving; flavour is the most-reported use motivation	Well supported as a driver of switching; unproven as a substitute for strength-seeking
Measured escalation	Pouch users demonstrably move up over time	One cross-sectional, retrospective, single-country survey: 16.8% up, 13.2% down, 51.4% unchanged	Not established. No prospective cohort exists

Common questions

So is strength creep a myth? No — it is undetermined, which is a different thing. Plenty of individuals genuinely do use stronger pouches than they started with. What has not been shown is that this is a general pattern with a pharmacological cause, and three alternative explanations are better evidenced than that one.

If I have gone up, does that mean I am more dependent? The honest answer is that the strength-and-dependence relationship is not clean where it has been measured. A 2026 Danish national survey of 1,201 users aged 15–29 found that pouches at 5 mg or more, and holds of more than fifteen minutes, were associated with reporting being very addicted — but the association peaked in the 10–14 mg band and fell back above 15 mg rather than continuing to climb. Cross-sectional data also cannot tell you which way the arrow points. I would not read a number on a can as a measure of anything about yourself.

Will blood nicotine just keep rising if I keep going up? Within a day, nicotine accumulates and then levels off; for oral products specifically, “Concentrations of nicotine in the blood rise gradually with the use of smokeless tobacco and plateau at about 30 min, with levels persisting and declining only slowly over 2 h or more”. Whether established users’ levels are stable across months or years is a different question, and I could not find any source that answers it. Do not let the within-day plateau stand in for the long-run one.

Is there a legal cap that stops this? Not in most places. The US position is a list of authorised products rather than a strength ceiling, and it has moved upward three times. Some markets do cap concentration — the picture is in strength caps by country. The authors of the German study argued for one: “A limit of nicotine content is warranted.” That is their conclusion in a journal article, not a formal regulatory position.

What should I do with all this? Change one variable at a time and write it down. Hold time, brand and labelled strength all move the dose, and two of them move it more than people expect. If you are comparing products, judging a pouch properly takes more than one can.

Sources

• Alqahtani et al., Patterns and characteristics of nicotine pouch use among adults with a history of cigarette smoking, Frontiers in Public Health, 2026 — PMC13310886 (strength trajectory; 10 mg preference; funding)
• Scoping review of population-based oral nicotine pouch research, Hawaii Journal of Health & Social Welfare, 2026 — PMC12994773 (absence of longitudinal evidence)
• Benowitz, Pharmacology of Nicotine: Addiction, Smoking-Induced Disease, and Therapeutics, Annu Rev Pharmacol Toxicol, 2009 — PMC2946180 (receptor upregulation; selective tolerance)
• Benowitz, Nicotine Addiction, N Engl J Med, 2010 — PMC2928221 (desensitisation; overnight resensitisation)
• Hukkanen, Jacob & Benowitz, nicotine disposition review — PMC2953858 (smokeless plateau at ~30 min)
• Perkins et al., Psychopharmacology, 2001 — PMID 11105943 (tolerance to aversive effects in naive volunteers)
• Benowitz, commentary on smokeless tobacco pH, Clin Pharmacol Ther, 2022 — PMC9035094 (pKa 8.0; the starter-product argument)
• The pH of Smokeless Tobacco Determines Nicotine Buccal Absorption: Results of a Randomized Crossover Trial, Clin Pharmacol Ther, 2022 — PMID 34826137 (fourfold pH effect; funding statement not readable)
• Brinkman et al., pH and free-base nicotine in 70 tobacco-free nicotine products, Tobacco Control — PMC12075619 (pH 4.68–9.49; label accuracy)
• A Randomized Crossover Clinical Study to Assess the Effect of Oral Nicotine Pouches Used for Different Durations on Plasma Nicotine Pharmacokinetics, J Clin Pharmacol, 2026 — PMC12709140 (extraction by hold time; BAT funding)
• Rabenstein et al., nicotine pouch pharmacokinetics, Front Pharmacol, 2024 — PMC11150668 (52% extraction; non-monotonic bioavailability; nicotine-free pouch and craving; BfR funding)
• Oral nicotine pouch pharmacokinetics and subjective responses, Psychopharmacology, 2022 — PMC9385814 (C_max 3.5–15.4 ng/mL; Altria funding)
• Pouch versus cigarette pharmacokinetics, Psychopharmacology, 2025 — PMID 41384973 (9 mg ZYN peak 27.9 ng/mL; nausea in light smokers; no competing interests declared)
• Flavoured versus unflavoured pouch crossover studies, Drug Alcohol Depend, 2026 — PMID 41579531 (equivalent nicotine, higher liking; Swedish Match / PMI employees)
• Oral nicotine pouch use motivations, Nicotine Tob Res, 2024 — PMID 37712111 (flavour availability as leading motivation)
• Arp et al., Danish §SMOKE survey, Addiction, 2026 — PMID 42902826 (strength and hold-time associations with self-perceived addiction)
• Review of oral nicotine pouch research funding, Exp Clin Psychopharmacol, 2025 — PMC11959675 (industry funding of the clinical literature; NIDA and FDA CTP funded)
• US Food and Drug Administration, Nicotine Pouch Products Authorized by the FDA — 43 products, content current as of 21 August 2026
• US Food and Drug Administration, FDA Authorizes 11 New Nicotine Pouches, 21 August 2026 — on labelled content versus delivery

Last verified 26 October 2026.

Nicotine is addictive. No tobacco or nicotine product is safe, and completely stopping is the lowest-risk option. This site is for adults who already use nicotine — 21+ in the United States, 18+ or your local legal age elsewhere. Nothing here is medical advice.